Tejas Savant
Stock Analyst at Morgan Stanley
(2.18)
# 2,645
Out of 4,784 analysts
226
Total ratings
38.52%
Success rate
-4.86%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $2.36 | +111.86% | 13 | Mar 25, 2025 | |
| GRAL GRAIL | Maintains: Equal-Weight | $16 → $20 | $26.93 | -25.73% | 2 | Mar 18, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $50 → $60 | $47.83 | +25.44% | 2 | Mar 6, 2025 | |
| NTRA Natera | Maintains: Overweight | $176 → $185 | $143.94 | +28.53% | 13 | Mar 5, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $28 → $26 | $9.16 | +183.84% | 13 | Feb 14, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $245 → $250 | $177.39 | +40.93% | 11 | Feb 11, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $150 → $136 | $80.00 | +70.00% | 7 | Feb 11, 2025 | |
| AVTR Avantor | Maintains: Overweight | $27 → $25 | $16.18 | +54.51% | 16 | Feb 10, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $647 → $678 | $500.16 | +35.56% | 14 | Jan 31, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $84 → $82 | $61.32 | +33.72% | 8 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $20.29 | +13.36% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $30.12 | -7.04% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $8.88 | +136.49% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.14 | +75.44% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $3 | $1.43 | +109.79% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $6.12 | +553.59% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $4.00 | +75.00% | 8 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $9.62 | +76.72% | 12 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $10 | $7.67 | +30.38% | 11 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $16 | $6.09 | +162.73% | 1 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.89 | +576.06% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $3.26 | +206.75% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $2.68 | +2.61% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $3.62 | +38.12% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.74 | +474.71% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $43.14 | +69.22% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $155.55 | +60.72% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.67 | +646.27% | 5 | May 12, 2022 |
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.36
Upside: +111.86%
GRAIL
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $26.93
Upside: -25.73%
Tempus AI
Mar 6, 2025
Maintains: Overweight
Price Target: $50 → $60
Current: $47.83
Upside: +25.44%
Natera
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $143.94
Upside: +28.53%
10x Genomics
Feb 14, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $9.16
Upside: +183.84%
IQVIA Holdings
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $177.39
Upside: +40.93%
Illumina
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $150 → $136
Current: $80.00
Upside: +70.00%
Avantor
Feb 10, 2025
Maintains: Overweight
Price Target: $27 → $25
Current: $16.18
Upside: +54.51%
Thermo Fisher Scientific
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $500.16
Upside: +35.56%
Hologic
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $84 → $82
Current: $61.32
Upside: +33.72%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $20.29
Upside: +13.36%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $30.12
Upside: -7.04%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $8.88
Upside: +136.49%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.14
Upside: +75.44%
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $1.43
Upside: +109.79%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $6.12
Upside: +553.59%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $4.00
Upside: +75.00%
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $9.62
Upside: +76.72%
Oct 24, 2023
Maintains: Equal-Weight
Price Target: $13 → $10
Current: $7.67
Upside: +30.38%
Aug 17, 2023
Initiates: Equal-Weight
Price Target: $16
Current: $6.09
Upside: +162.73%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.89
Upside: +576.06%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $3.26
Upside: +206.75%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $2.68
Upside: +2.61%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $3.62
Upside: +38.12%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.74
Upside: +474.71%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $43.14
Upside: +69.22%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $155.55
Upside: +60.72%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.67
Upside: +646.27%